1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAACR Gertrude B. Elion Cancer Research Award is sponsored by American Association for Cancer Research (AACR) and GlaxoSmithKline. Encourages junior faculty to conduct research on cancer etiology, diagnosis, treatment, or prevention, offering $225,000 for one year.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
AACR Gertrude B. Elion Cancer Research Award | American Association for Cancer Research AACR Annual Meeting News: Read the Latest Session Recaps from the Official News Website Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.
Patient / Caregivers / Public Researchers / Professionals AACR Gertrude B. Elion Cancer Research Award With generous support from GlaxoSmithKline, the AACR Gertrude B. Elion Cancer Research Award encourages and supports tenure-eligible junior faculty to conduct research in cancer etiology, diagnosis, treatment, or prevention.
University of Pennsylvania Philadelphia, Pennsylvania Harness insights from chromatin priming for early interception of basal-like breast cancer Scientific Statement of Research Basal-like breast cancer (BLBC) is an aggressive malignancy causing substantial morbidity and mortality. It occurs either as a sporadic form that affects a wide population or as a hereditary form with high penetrance in carriers of oncogenic mutations.
Current BLBC treatment depends on non-specific chemotherapy and invasive prophylactic surgery, highlighting the urgent need for targeted interception strategies, which require deeper insight into the early events driving BLBC onset. Dr. Carman Li’s research seeks to elucidate the molecular and epigenetic mechanisms underlying both hereditary and sporadic BLBC.
By employing innovative genetically engineered mouse models, patient-derived samples, and multi-omics profiling, this study aims to uncover the earliest processes fueling BLBC initiation. Understanding and disrupting these early mechanisms will enable the development of precise interventions that stop cancer growth at its inception.
Dr. Li earned her undergraduate degree from Princeton University and conducted her doctoral research at Massachusetts Institutes of Technology. She completed her postdoctoral training at Harvard Medical School, where she investigated mammary cell state plasticity under genetic and physiological cancer risk factors.
Dr. Li is currently an assistant professor of cancer biology at the University of Pennsylvania and a core investigator at the Basser Center for BRCA. Her lab studies the driving mechanisms and targetable vulnerabilities of hereditary cancer and their implications for sporadic cancer by combining genetic mouse models, organoids, and genomic tools. Acknowledgement of Support “I am deeply honored and excited to receive the AACR Gertrude B.
Elion Cancer Research Award. As my lab’s very first extramural grant, this support serves as a powerful catalyst, enabling us to pursue bold, high-risk ideas and accelerating our efforts to uncover actionable mechanisms for cancer interception and prevention.
” Cold Spring Harbor Laboratory Cold Spring Harbor, New York Deconstructing benign-to-malignant transition at spatiotemporal resolution Scientific Statement of Research Early onset cancer is increasing worldwide, and colorectal cancer (CRC) is now the first and second leading cause of cancer-related deaths in men and women under 50, respectively.
These cancers are often highly aggressive at diagnosis, highlighting the pressing need for improved methods of early detection and prevention. Unfortunately, our understanding of early cancer is rudimentary, and we do not know why some benign polyps progress to malignant cancer while most do not.
Dr. Westcott plans to comprehensively profile the kinetics and spatial biology of benign-to-malignant transition using a combination of rare patient samples and innovative mouse models that capture the stepwise progression and immune interactions of human CRC. Combined with cutting-edge spatial ‘omics’ technologies, this work aims to elucidate the pioneering molecular and cellular events underlying early cancer progression.
Dr. Westcott received his doctorate from the University of California, San Franscisco, where he spearheaded comparative studies of mutational processes in chemical carcinogenesis and genetically engineered mouse models of cancer. As a postdoctoral researcher at the Massachusetts Institute of Technology, he developed innovative cancer models that capture mutational and immune interactions of human cancer.
In 2022, Dr. Westcott started his independent research group at Cold Spring Harbor Laboratory. With a background in cancer genetics and immunology, he is broadly interested in how cancer talks with the immune system and how this conversation changes through major transitions in cancer evolution. This focus was shaped by his graduate and postdoctoral training.
Acknowledgment of Support “It is a huge honor to be this year’s AACR Gertrude B. Elion Cancer Research Awardee. This generous support from the AACR and GlaxoSmithKline is an early career catalyst and a boon to my laboratory that will enable us to pursue daring studies that literally would not be possible otherwise.
” block needs to be placed in the location where the link block will be displayed--> Cancer Researchers / Other Health Care Professionals Career Development Awards
According to the current listing, eligibility includes: Nonprofit institutions conducting cancer research. Confirm the full requirements in the official notice before applying.
The current listing shows $225,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 16, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
AACR Gertrude B. Elion Cancer Research Award is funded by American Association for Cancer Research (AACR) and GlaxoSmithKline. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article